| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/14/2022 | 17.37% | Truist Securities | $52 → $55 | Maintains | Buy |
| 07/07/2022 | 2.43% | Raymond James | $50 → $48 | Maintains | Outperform |
| 04/28/2022 | 6.7% | Raymond James | $57 → $50 | Maintains | Outperform |
| 12/30/2021 | 21.64% | Stephens & Co. | $56 → $57 | Maintains | Equal-Weight |
| 11/01/2021 | 21.64% | Raymond James | $55 → $57 | Maintains | Outperform |
| 09/30/2021 | 19.5% | Stephens & Co. | → $56 | Downgrades | Overweight → Equal-Weight |
| 04/07/2021 | 28.04% | Raymond James | $46 → $60 | Downgrades | Strong Buy → Outperform |
| 03/30/2021 | — | DA Davidson | Downgrades | Buy → Neutral | |
| 02/01/2021 | -1.84% | Raymond James | $44 → $46 | Maintains | Strong Buy |
| 12/11/2020 | -6.1% | Raymond James | $33 → $44 | Maintains | Strong Buy |
| 10/26/2020 | -25.31% | Piper Sandler | $28 → $35 | Maintains | Overweight |
| 10/26/2020 | -29.58% | Raymond James | $27 → $33 | Maintains | Strong Buy |
| 10/19/2020 | -31.71% | Stephens & Co. | → $32 | Reinstates | → Overweight |
| 09/30/2020 | -40.25% | Piper Sandler | $29 → $28 | Maintains | Overweight |
| 09/23/2020 | -42.38% | Raymond James | → $27 | Upgrades | Outperform → Strong Buy |
| 07/29/2020 | -38.11% | Piper Sandler | → $29 | Reinstates | → Overweight |
| 07/28/2020 | -35.98% | SunTrust Robinson Humphrey | $29 → $30 | Maintains | Buy |
| 05/22/2020 | -46.65% | DA Davidson | → $25 | Initiates Coverage On | → Buy |
| 05/05/2020 | -38.11% | SunTrust Robinson Humphrey | $28 → $29 | Maintains | Buy |
| 04/06/2020 | -35.98% | SunTrust Robinson Humphrey | $36 → $30 | Maintains | Buy |
| 01/02/2020 | 6.7% | SunTrust Robinson Humphrey | $47 → $50 | Maintains | Buy |
| 09/25/2019 | -1.84% | Piper Sandler | $47 → $46 | Maintains | Overweight |
| 08/27/2019 | -3.97% | SunTrust Robinson Humphrey | $47 → $45 | Maintains | Buy |
| 07/12/2019 | -3.97% | Raymond James | → $45 | Initiates Coverage On | → Outperform |
| 01/29/2019 | 2.43% | SunTrust Robinson Humphrey | → $48 | Upgrades | Hold → Buy |
| 12/18/2018 | 2.43% | Piper Sandler | $49.5 → $48 | Upgrades | Neutral → Overweight |
| 06/26/2018 | — | SunTrust Robinson Humphrey | Downgrades | Buy → Hold | |
| 11/20/2017 | — | Keefe, Bruyette & Woods | Upgrades | Market Perform → Outperform | |
| 10/05/2017 | 1.37% | Piper Sandler | → $47.5 | Assumes | Neutral → Neutral |
Ameris Questions & Answers
The latest price target for Ameris (NASDAQ: ABCB) was reported by Truist Securities on September 14, 2022. The analyst firm set a price target for $55.00 expecting ABCB to rise to within 12 months (a possible 17.37% upside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for Ameris (NASDAQ: ABCB) was provided by Truist Securities, and Ameris maintained their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ameris, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ameris was filed on September 14, 2022 so you should expect the next rating to be made available sometime around September 14, 2023.
While ratings are subjective and will change, the latest Ameris (ABCB) rating was a maintained with a price target of $52.00 to $55.00. The current price Ameris (ABCB) is trading at is $46.86, which is out of the analyst's predicted range.